The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2021 | Smart Stop: Moving away from R-CHOP in DLBCL
Jason Westin, MD, FACP, University of Texas MD Anderson Center, Houston, TX, discusses the Phase II Smart Stop study (NCT04978584) of lenalidomide, rituximab, tafasitamab, and acalabrutinib (LTRA) alone or with CHOP in treatment-naïve patients with non-germinal center (non-GCB) diffuse large B-cell lymphoma (DLBCL). Patients will receive four cycles of LTRA and will subsequently either receive chemotherapy or no further treatment. The trial aims to build on the Smart Start trial (NCT02636322) and demonstrate the efficacy of chemotherapy-free regiments in DLBCL. This interview took place at the 63rd ASH Annual Meeting and Exposition congress in Atlanta, GA.
